1. Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L. (March 2022) Authors: Popat, Sanjay; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James; Han, Ji-Youn; Hochmair, Maximilian; Lee, Ki Hyeong; Delmonte, Angelo; Garcia Campelo, Maria; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander; Gettinger, Scott; Tiseo, Marcello; Lin, Huamao; Liu, Yuy... Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. (2016) Authors: Qian, Jack M.; Yu, James B.; Gettinger, Scott; Chiang, Veronica L.S. Journal: Cancer treatment communications Issue: Volume 6(2016) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. (6th November 2014) Authors: Kowanetz, Marcin; Rabe, Christina; Xiao, Yuanyuan; Wu, Qun J; Koeppen, Hartmut; Leddy, Cecilia; Patel, Rajesh D; Powderly, John; Kohrt, Holbrook; Gettinger, Scott; Soria, Jean-Charles; Herbst, Roy S; Desai, Rupal; Denker, Mitchell; Ruppel, Jane; Boe, Marigold; Nakamura, Rin; Fu, Ling; Sumiyoshi, ... Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (November 2017) Authors: Horn, Leora; Gettinger, Scott; Camidge, D. Ross; Smit, Egbert F.; Janjigian, Yelena Y.; Miller, Vincent A.; Pao, William; Freiwald, Matthias; Fan, Jean; Wang, Bushi; Chand, Vikram K.; Groen, Harry J.M. Journal: Lung cancer Issue: Volume 113(2017) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer. (6th November 2014) Authors: Dhodapkar, Kavita; Verma, Rakesh; Sznol, Mario; Boddupalli, Chandra Sekhar; Gettinger, Scott; Kluger, Harriet; Dhodapkar, Madhav; Das, Rituparna Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Issue 7 (1st March 2021) Authors: Borghaei, Hossein; Gettinger, Scott; Vokes, Everett E.; Chow, Laura Q. M.; Burgio, Marco Angelo; de Castro Carpeno, Javier; Pluzanski, Adam; Arrieta, Oscar; Frontera, Osvaldo Arén; Chiari, Rita; Butts, Charles; Wójcik-Tomaszewska, Joanna; Coudert, Bruno; Garassino, Marina Chiara; Ready, Neal; Fel... Journal: Journal of clinical oncology Issue: Volume 39:Issue 7(2021) Page Start: 723 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Issue 10 (October 2019) Authors: Antonia, Scott J; Borghaei, Hossein; Ramalingam, Suresh S; Horn, Leora; De Castro Carpeño, Javier; Pluzanski, Adam; Burgio, Marco A; Garassino, Marina; Chow, Laura Q M; Gettinger, Scott; Crinò, Lucio; Planchard, David; Butts, Charles; Drilon, Alexander; Wojcik-Tomaszewska, Joanna; Otterson, Grego... Journal: Lancet oncology Issue: Volume 20:Issue 10(2019) Page Start: 1395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1. (7th November 2013) Authors: Kohrt, Holbrook; Kowanetz, Marcin; Gettinger, Scott; Powderly, John; Koeppen, Hartmut; Sosman, Jeffrey A; Cruz, Cristina; Xiao, Yuanyuan; Mokatrin, Ahmad; Fine, Gregg; Chen, Daniel S; Hodi, F Stephen Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective. Issue 2 (March 2020) Authors: Hafez, Navid; Gettinger, Scott Journal: Cancer journal Issue: Volume 26:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. Issue 7 (20th March 2020) Authors: Hellmann, Matthew D.; Gettinger, Scott; Chow, Laura Q. M.; Gordon, Michael; Awad, Mark M.; Cha, Edward; Gong, Xiaohua; Zhou, Gongfu; Walker, Chris; Leopold, Lance; Heist, Rebecca S. Journal: International journal of cancer Issue: Volume 147:Issue 7(2020) Page Start: 1963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗